DMAA
DMAA
Drugs Made In America Acquisition Corp. Ordinary SharesIncome Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $0 | $2.09M ▲ | $-1.76M ▼ | 0% | $-0 ▼ | $-2.09M ▼ |
| Q3-2025 | $0 | $263.7K ▲ | $2.18M ▼ | 0% | $0.07 ▲ | $-263.7K ▼ |
| Q2-2025 | $0 | $131.92K ▼ | $2.29M ▲ | 0% | $0.07 ▼ | $-131.92K ▲ |
| Q1-2025 | $0 | $330.93K ▲ | $1.25M ▲ | 0% | $130.51 ▲ | $-330.93K ▼ |
| Q4-2024 | $0 | $279.88 | $-279 | 0% | $-0.03 | $0 |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $6.14K ▲ | $239.92M ▲ | $7.28M ▼ | $232.64M ▲ |
| Q3-2025 | $717 ▼ | $237.63M ▲ | $7.36M ▲ | $230.28M ▲ |
| Q2-2025 | $822 ▼ | $235.21M ▲ | $7.2M ▼ | $228M ▲ |
| Q1-2025 | $923 ▼ | $232.81M ▲ | $7.25M ▲ | $225.56M ▲ |
| Q4-2024 | $1.35K | $550.82 | $795.67 | $-244 |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $-1.76M ▼ | $-125.18K ▼ | $0 ▼ | $130.6K ▲ | $5.42K ▲ | $-125.18K ▼ |
| Q3-2025 | $785.09K ▼ | $137.91K ▲ | $231.15M ▲ | $-231.3M ▼ | $-105 ▲ | $137.9K ▲ |
| Q2-2025 | $3.69M ▲ | $-300.67K ▼ | $-231.15M | $231.47M ▲ | $-1.27K ▼ | $-300.67K ▼ |
| Q1-2025 | $1.25M ▲ | $-251.24K ▼ | $-231.15M ▼ | $231.4M ▲ | $-428 ▲ | $-251.24K ▼ |
| Q4-2024 | $-279 | $-106 | $0 | $-638 | $-744 | $-123 |
5-Year Trend Analysis
A comprehensive look at Drugs Made In America Acquisition Corp. Ordinary Shares's financial evolution and strategic trajectory over the past five years.
DMAA’s financial structure features ample liquidity and no financial debt, limiting near-term solvency risk while it pursues a merger. Reported earnings are positive for the period, and cash levels are supported by financing inflows. Strategically, the identified target, Power Analytics, offers a well-established technology platform, deep domain expertise in mission-critical systems, and a portfolio of advanced AI and cybersecurity-related solutions that could underpin a compelling operating story post-merger.
At present, DMAA has no revenue and negative operating and free cash flow, indicating it is not a self-sustaining business. Negative equity and retained earnings highlight accumulated losses and a fragile capital structure. The company’s future is highly dependent on a single, still non-binding merger transaction, with execution, regulatory, and timing risks. Even if the deal closes, the combined entity will face intense competition in industrial software, AI, and cybersecurity, as well as demanding regulatory and reliability expectations in its end markets.
Near-term, DMAA’s outlook is dominated by the outcome of the de‑SPAC process rather than by its current financial performance. If the merger with Power Analytics proceeds to completion, the profile will shift from a cash shell to an operating company focused on AI-driven analytics and quantum-safe technologies for high-stakes industries. The long-term trajectory will then depend on Power Analytics’ ability to convert its technology and certifications into sustainable revenue growth, recurring cash flow, and continued innovation, all of which remain uncertain until more detailed operating data becomes available.
About Drugs Made In America Acquisition Corp. Ordinary Shares
https://dmaacorp.comDrugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $0 | $2.09M ▲ | $-1.76M ▼ | 0% | $-0 ▼ | $-2.09M ▼ |
| Q3-2025 | $0 | $263.7K ▲ | $2.18M ▼ | 0% | $0.07 ▲ | $-263.7K ▼ |
| Q2-2025 | $0 | $131.92K ▼ | $2.29M ▲ | 0% | $0.07 ▼ | $-131.92K ▲ |
| Q1-2025 | $0 | $330.93K ▲ | $1.25M ▲ | 0% | $130.51 ▲ | $-330.93K ▼ |
| Q4-2024 | $0 | $279.88 | $-279 | 0% | $-0.03 | $0 |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $6.14K ▲ | $239.92M ▲ | $7.28M ▼ | $232.64M ▲ |
| Q3-2025 | $717 ▼ | $237.63M ▲ | $7.36M ▲ | $230.28M ▲ |
| Q2-2025 | $822 ▼ | $235.21M ▲ | $7.2M ▼ | $228M ▲ |
| Q1-2025 | $923 ▼ | $232.81M ▲ | $7.25M ▲ | $225.56M ▲ |
| Q4-2024 | $1.35K | $550.82 | $795.67 | $-244 |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $-1.76M ▼ | $-125.18K ▼ | $0 ▼ | $130.6K ▲ | $5.42K ▲ | $-125.18K ▼ |
| Q3-2025 | $785.09K ▼ | $137.91K ▲ | $231.15M ▲ | $-231.3M ▼ | $-105 ▲ | $137.9K ▲ |
| Q2-2025 | $3.69M ▲ | $-300.67K ▼ | $-231.15M | $231.47M ▲ | $-1.27K ▼ | $-300.67K ▼ |
| Q1-2025 | $1.25M ▲ | $-251.24K ▼ | $-231.15M ▼ | $231.4M ▲ | $-428 ▲ | $-251.24K ▼ |
| Q4-2024 | $-279 | $-106 | $0 | $-638 | $-744 | $-123 |
5-Year Trend Analysis
A comprehensive look at Drugs Made In America Acquisition Corp. Ordinary Shares's financial evolution and strategic trajectory over the past five years.
DMAA’s financial structure features ample liquidity and no financial debt, limiting near-term solvency risk while it pursues a merger. Reported earnings are positive for the period, and cash levels are supported by financing inflows. Strategically, the identified target, Power Analytics, offers a well-established technology platform, deep domain expertise in mission-critical systems, and a portfolio of advanced AI and cybersecurity-related solutions that could underpin a compelling operating story post-merger.
At present, DMAA has no revenue and negative operating and free cash flow, indicating it is not a self-sustaining business. Negative equity and retained earnings highlight accumulated losses and a fragile capital structure. The company’s future is highly dependent on a single, still non-binding merger transaction, with execution, regulatory, and timing risks. Even if the deal closes, the combined entity will face intense competition in industrial software, AI, and cybersecurity, as well as demanding regulatory and reliability expectations in its end markets.
Near-term, DMAA’s outlook is dominated by the outcome of the de‑SPAC process rather than by its current financial performance. If the merger with Power Analytics proceeds to completion, the profile will shift from a cash shell to an operating company focused on AI-driven analytics and quantum-safe technologies for high-stakes industries. The long-term trajectory will then depend on Power Analytics’ ability to convert its technology and certifications into sustainable revenue growth, recurring cash flow, and continued innovation, all of which remain uncertain until more detailed operating data becomes available.

CEO
Roger Bendelac
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C+
Price Target
Institutional Ownership
KARPUS MANAGEMENT, INC.
Shares:2.55M
Value:$26.83M
FIRST TRUST CAPITAL MANAGEMENT L.P.
Shares:2.24M
Value:$23.61M
POLAR ASSET MANAGEMENT PARTNERS INC.
Shares:1.9M
Value:$20.01M
Summary
Showing Top 3 of 41

